Swift Biosciences has developed a line of myT™ Primers, highly selective qPCR reagents for detection of mutations. myT Primers have unique structural and thermodynamic properties that enable sensitive mismatch discrimination.

The distinctive physical characteristics of myT Primers enable both high sensitivity and specificity, making them ideal for cancer research and diagnostic research applications. Assays based on myT Primer reagents are easy to optimize and give robust performance. To date, myT Primers have been developed for the common mutations in BRAF and KRAS genes.

Key Points:

• myT Primers exhibit high analytical selectivity for mutation detection and can achieve single copy sensitivity and specificity
• myT Primers display sensitive mutation detection on both FFPE and fresh frozen specimens
• Capable of genotyping KRAS in a single cancer cell present in a blood sample
• Superior performance of myT Primers is well suited for emerging applications such as circulating tumor cells (CTCs), serum, plasma and needle biopsies
• myT Primers work in conventional qPCR machines using standard, 'single tube' protocols
• Easy and quick to develop assays for new templates